This investigation finds sulforaphane reduces doxorubicin cytotoxicity in cardiac cells, highlighting the wnt/beta-catenin pathway's role.
This study investigates the role of sulforaphane (SFN) and quercetin (QCT) in alleviating the oxidative stress and modulation of cellular responses induced by doxorubicin (DOX) in rat cardiomyoblast cells H9c2. The potential mechanisms involving Wnt/β-catenin signaling and antioxidant response were determined. We found that SFN effectively mitigated DOX-induced cytotoxicity in H9c2 cells. These effects of SFN significantly exceeded the influence of QCT. Levels of superoxide dismutase isoforms 1 (SOD-1) and 2 (SOD-2) were upregulated following SFN and QCT pretreatment in cells exposed to effects of DOX. Additionally, β-catenin levels were increased following both SFN and QCT treatment, even in the presence of doxorubicin. Elevated β-catenin levels for QCT were associated with increased phosphorylation and inactivation of glycogen synthase kinase 3-β. The critical role of Wnt/β-catenin signaling in responses of H9c2 cells to effects of DOX was confirmed using Wnt/β-catenin inhibitor WIKI-4. This inhibitor increased the sensitivity of cells to DOX, and the decreased cellular viability after pretreatment with WIKI-4 was linked to SOD activities' inhibition. Conclusively, sulforaphane and quercetin exert a protective effect against doxorubicin-induced cytotoxicity in H9c2 cells through the Wnt/β-catenin pathway as well as in association with modulation of enzymes related to the cellular antioxidant response.
No takes yet. Share an insight, caveat, or question.
Líšková et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: